Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

References

• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–14. doi:10.1084/jem.192.7.1027. PMID: 11015443.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51. doi: 10.1016/s1074-7613(00)80089-8. PMID: 10485649.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T regs in the melanoma tumor microenvironment is driven by CD8 + T cells. Sci Transl Med. 2013;5(200):200ra116. doi: 10.1126/scitranslmed.3006504. PMID: 23986400.
   PubMed Web of Science ®Google Scholar
• Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK, Wolchok JD, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol. 2020;38:1655–63. doi:10.1200/JCO.19.01464. PMID: 32053428.
   PubMedGoogle Scholar
• McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, et al. Survival, durable response, and long-term safety in patients with Previously treated Advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33:2013–20. doi:10.1200/JCO.2014.58.1041. PMID: 25800770.
   PubMed Web of Science ®Google Scholar
• Rosner S, Reuss JE, Forde PM. PD-1 blockade in early-stage lung cancer. Annu Rev Med. 2019;70(1):425–35. doi: 10.1146/annurev-med-050217-025205. PMID: 30355264.
   PubMedGoogle Scholar
• Jiang Y, Zhao X, Fu J, Wang H. Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade. Front Immunol. 2020;11:339. doi:10.3389/fimmu.2020.00339. PMID: 32226426.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40. doi:10.1172/JCI91190. PMID: 28650338.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92. doi:10.1016/S1470-2045(17)30616-2. PMID: 28967485.
   PubMed Web of Science ®Google Scholar
• Alsaihati BA, Ho KL, Watson J, Feng Y, Wang T, Dobbin KK, Zhao S. Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. Nat Commun. 2021;12(1):4670. doi: 10.1038/s41467-021-24836-9. PMID: 34344882.
   PubMed Web of Science ®Google Scholar
• Andris-Widhopf J, Steinberger P, Fuller R, Rader C, Barbas CF. Generation of antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. In: Barbas C, Burton DR, Scott JK, and Silverman GJ, editors. Phage display: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. p. 9.1.
   Google Scholar
• Manso T, Folch G, Giudicelli V, Jabado-Michaloud J, Kushwaha A, Nguefack Ngoune V, Georga M, Papadaki A, Debbagh C, Pegorier P, et al. IMGT® databases, related tools and web resources through three main axes of research and development. Nucleic Acids Res. 2022;50(D1):D1262–D72. doi:10.1093/nar/gkab1136. PMID: 34875068.
   PubMed Web of Science ®Google Scholar
• Bao Y, Guo Y, Xiao S, Zhao Z. Molecular characterization of the VH repertoire in Canis familiaris. Vet Immunol Immunopathol. 2010;137:64–75. doi:10.1016/j.vetimm.2010.04.011. PMID: 20483487.
   PubMed Web of Science ®Google Scholar
• Hwang MH, Darzentas N, Bienzle D, Moore PF, Morrison J, Keller SM. Characterization of the canine immunoglobulin heavy chain repertoire by next generation sequencing. Vet Immunol Immunopathol. 2018;202:181–90. doi:10.1016/j.vetimm.2018.07.002. PMID: 30078594.
   PubMed Web of Science ®Google Scholar
• Martin J, Ponstingl H, Lefranc MP, Archer J, Sargan D, Bradley A. Comprehensive annotation and evolutionary insights into the canine (Canis lupus familiaris) antigen receptor loci. Immunogenetics. 2018;70(4):223–36. doi: 10.1007/s00251-017-1028-0. PMID: 28924718.
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Dunkle WE, Bammert GF, Wilson TL, Krishnan A, Dunham SA, Ippolito GC, Bainbridge G. Fundamental characteristics of the expressed immunoglobulin VH and VL repertoire in different canine breeds in comparison with those of humans and mice. Mol Immunol. 2014;59:71–78. doi:10.1016/j.molimm.2014.01.010. PMID: 24509215.
   PubMed Web of Science ®Google Scholar
• Mason NJ, Chester N, Xiong A, Rotolo A, Wu Y, Yoshimoto S, Glassman P, Gulendran G, Siegel DL. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. MAbs. 2021;13(1):2004638. doi: 10.1080/19420862.2021.2004638. PMID: 34856888.
   PubMed Web of Science ®Google Scholar
• Rader CS, Steinberger P, Barbas CF. Selection from antibody libraries. In: Barbas C, Burton DR, Scott JK, and Silverman GJ, editors. Phage display: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. p. 10.1.
   Google Scholar
• Rader C, Steinberger PR, Barbas CF. Analysis of selected antibodies. In: Barbas C, Burton DR, Scott JK, and Silverman GJ, editors. Phage display: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. p. 11.1.
   Google Scholar
• Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu Q, Li Y, Zhang T, Zhang Y, Cui X, et al. Tislelizumab uniquely binds to the CC′ loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021;11(3):782–92. doi:10.1002/2211-5463.13102. PMID: 33527708.
   PubMed Web of Science ®Google Scholar
• Zha H, Jiang Y, Wang X, Shang J, Wang N, Yu L, Zhao W, Li Z, An J, Zhang X, et al. Non-canonical PD-1 signaling in cancer and its potential implications in clinic. J Immunother Cancer. 2021;9(2):e001230. doi:10.1136/jitc-2020-001230. PMID: 33593825.
   PubMed Web of Science ®Google Scholar
• Centanni M, Moes D, Troconiz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58(7):835–57. doi: 10.1007/s40262-019-00748-2. PMID: 30815848.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, et al. Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with Advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–93. doi:10.1158/1078-0432.CCR-14-2607. PMID: 25977344.
   PubMed Web of Science ®Google Scholar
• Andre AS, Moutinho I, Dias JNR, Aires-da-Silva F. In vivo phage display: a promising selection strategy for the improvement of antibody targeting and drug delivery properties. Front Microbiol. 2022;13:962124. doi:10.3389/fmicb.2022.962124. PMID: 36225354.
   PubMed Web of Science ®Google Scholar
• Igase M, Inanaga S, Tani K, Nakaichi M, Sakai Y, Sakurai M, Kato M, Tsukui T, Mizuno T. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report. Vet Comp Oncol. 2022;20:901–05. doi:10.1111/vco.12829. PMID: 35535636.
   PubMed Web of Science ®Google Scholar
• Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, Sakai Y, Noguchi S, Kato M, Tsukui T, et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020;10(1):18311. doi:10.1038/s41598-020-75533-4. PMID: 33110170.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–01. doi: 10.1056/NEJMc1713444. PMID: 29262275.
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207–18. doi:10.1056/NEJMoa2017699. PMID: 33264544.
   PubMed Web of Science ®Google Scholar
• Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMmr/MSI-H colorectal cancer. Front Oncol. 2019;9:396. doi:10.3389/fonc.2019.00396. PMID: 31139574.
   PubMed Web of Science ®Google Scholar
• Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor–transduced human T cells in solid tumors. Clin Cancer Res. 2014;20(16):4262–73. doi:10.1158/1078-0432.CCR-13-2627. PMID: 24919573.
   PubMed Web of Science ®Google Scholar
• Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, Ruella M, Bhattacharyya S, Wherry EJ, Schuster SJ. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026–38. doi: 10.1182/blood.2021012634. PMID: 34496014.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O’Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent Pembrolizumab. Cancer Discov. 2021;11(11):2748–63. doi:10.1158/2159-8290.CD-21-0407. PMID: 34266984.
   PubMed Web of Science ®Google Scholar
• Junker F, Gulati P, Wessels U, Seeber S, Stubenrauch KG, Codarri-Deak L, Markert C, Klein C, Camillo Teixeira P, Kao H. A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. Cytometry A. 2021;99(8):832–43. doi: 10.1002/cyto.a.24334. PMID: 33704890.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4(1):72. doi: 10.1186/s40425-016-0177-2. PMID: 27879974.
   PubMedGoogle Scholar
• Hirsch I, Goldstein DA, Tannock IF, Butler MO, Gilbert DC. Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. Nat Med. 2022;28(11):2236–37. doi: 10.1038/s41591-022-02029-1. PMID: 36202999.
   PubMed Web of Science ®Google Scholar
• Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022;12:906251. doi:10.3389/fonc.2022.906251. PMID: 35795044.
   PubMedGoogle Scholar
• Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O’Connor CM, Powell DJ Jr., Mason NJ. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol Ther. 2016;24:1602–14. doi:10.1038/mt.2016.146. PMID: 27401141.
   PubMed Web of Science ®Google Scholar
• Elia M, Andris-Widhopf J, Fuller R, Barbas CF. Production and purification of Fab and scFv. In: Barbas C, Burton DR, Scott JK, and Silverman GJ, editors. Phage display: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. p. 12.1.
   Google Scholar
• Rotolo A, Atherton MJ, Kasper BT, Haran KP, Mason NJ. Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer. STAR Protoc. 2021;2(4):100905. doi: 10.1016/j.xpro.2021.100905. PMID: 34746864.
   PubMedGoogle Scholar
• Panjwani MK, Atherton MJ, MaloneyHuss MA, Haran KP, Xiong A, Gupta M, Kulikovsaya I, Lacey SF, Mason NJ. Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology. 2020;9(1):1676615. doi: 10.1080/2162402X.2019.1676615. PMID: 32002286.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18. doi:10.1016/S1470-2045(15)00083-2. PMID: 26115796.
   PubMed Web of Science ®Google Scholar